Publicacións en colaboración con investigadores/as de University of Oxford (23)

2023

  1. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists

    Communications biology, Vol. 6, Núm. 1, pp. 376

2022

  1. Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 12

2020

  1. Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway

    International Immunopharmacology, Vol. 89

2017

  1. Gefitinib and EGFR gene copy number aberrations in esophageal cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287

2016

  1. IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 95, Núm. 5, pp. 1367-1377

  2. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

    PLoS Pathogens, Vol. 12, Núm. 7

2014

  1. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904

2009

  1. Proteomic analysis of HepaRG cells: A novel cell line that supports hepatitis B virus infection

    Journal of Proteome Research, Vol. 8, Núm. 1, pp. 118-122

  2. Proteomic analysis of integrin αIIbβ3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions

    Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 10, pp. 1718-1726

2008

  1. A microtubule interactome: Complexes with roles in cell cycle and mitosis

    PLoS Biology, Vol. 6, Núm. 4, pp. 785-795

2007

  1. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein

    Molecular and Cellular Proteomics, Vol. 6, Núm. 3, pp. 548-564

  2. Biomarker discovery from uveal melanoma secretomes: Identification of gp100 and cathepsin D in patient serum

    Journal of Proteome Research, Vol. 6, Núm. 7, pp. 2802-2811

2006

  1. A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: Involvement of G6f, a novel platelet Grb2-binding membrane adapter

    Proteomics, Vol. 6, Núm. 19, pp. 5332-5343

  2. Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara

    Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1764, Núm. 5, pp. 863-871

  3. Proteome analysis of signaling cascades in human platelets

    Blood Cells, Molecules, and Diseases, Vol. 36, Núm. 2, pp. 152-156

  4. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker

    International Journal of Cancer, Vol. 119, Núm. 5, pp. 1014-1022

2005

  1. Applying proteomics technology to platelet research

    Mass Spectrometry Reviews, Vol. 24, Núm. 6, pp. 918-930

  2. Nef-mediated lipid raft exclusion of UbcH7 inhibits Cbl activity in T cells to positively regulate signaling

    Immunity, Vol. 23, Núm. 6, pp. 621-634

  3. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS

    Proteomics, Vol. 5, Núm. 18, pp. 4980-4993

2004

  1. Abnormal cell cycle regulation in primary human uveal melanoma cultures

    Journal of Cellular Biochemistry, Vol. 93, Núm. 4, pp. 708-720